Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6V0KY)

Drug Name
Xmab-2513 Drug Info
Synonyms XENP-0367; XENP-0522; XmAb antibodies (infusion, cancer), Xencor; Anti-CD30 humanized mAb (infusion, cancer), Xencor
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM6V0KY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Lymphocyte activation antigen CD30 (TNFRSF8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brentuximab vedotin DMWLC57 Hodgkin lymphoma 2B30 Approved [3]
AFM13 DMN45IC Hodgkin lymphoma 2B30 Phase 2 [4]
Iratumumab DMI874B Lymphoma 2A80-2A86 Phase 2 [5]
SGN-30 DMJ9M5D Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
CAR-T cells targeting CD30 DML0KWM Non-hodgkin lymphoma 2B33.5 Phase 2 [7]
CAR-T cells targeting CD30 DML0KWM Non-hodgkin lymphoma 2B33.5 Phase 2 [8]
TT11X DMW3M7X Hodgkin lymphoma 2B30 Phase 2 [9]
TT20X DMHGI09 Aggressive cancer 2A00-2F9Z Phase 2 [9]
4SCAR19 and 4SCAR30 DMUYFS1 B-cell lymphoma 2A86 Phase 1/2 [10]
Anti-CD30 CAR T cells DM8139V Lymphoma 2A80-2A86 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte activation antigen CD30 (TNFRSF8) TT2GM5R TNR8_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT00606645) Safety Study of XmAb2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma. U.S. National Institutes of Health.
2 Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol (Meeting Abstracts) May 2009 vol. 27 no. 15S 8531.
3 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
4 Clinical pipeline report, company report or official report of Affimed Therapeutics.
5 Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
6 The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
7 ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
8 ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
9 Clinical pipeline report, company report or official report of Tessa Therapeutics
10 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
11 ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)